Didox and resveratrol sensitize colorectal cancer cells to doxorubicin via activating apoptosis and ameliorating P-glycoprotein activity

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Khaleel, Sahar A ^a   Al Abd, Ahmed M ^b   Ali, Azza A ^a   Abdel Naim, Ashraf B ^c  

^a Al Azhar University   (Egypt)

^b NATIONAL RESEARCH CENTRE   (Egypt)

^c Ain Shams University   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

3,4-DIHYDROXYBENZOHYDROXAMIC ACID; ANTINEOPLASTIC AGENT; DOXORUBICIN; HYDROXAMIC ACID; MULTIDRUG RESISTANCE PROTEIN 1; RESVERATROL; STILBENE DERIVATIVE;

APOPTOSIS; CELL SURVIVAL; COLORECTAL TUMOR; DRUG EFFECT; DRUG POTENTIATION; GENE EXPRESSION REGULATION; HCT 116 CELL LINE; HT-29 CELL LINE; HUMAN; METABOLISM;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; ATP-BINDING CASSETTE, SUB-FAMILY B, MEMBER 1; CELL SURVIVAL; COLORECTAL NEOPLASMS; DOXORUBICIN; DRUG SYNERGISM; GENE EXPRESSION REGULATION, NEOPLASTIC; HCT116 CELLS; HT29 CELLS; HUMANS; HYDROXAMIC ACIDS; STILBENES;

EID: 84995376528     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep36855     Document Type: Article

References (68)

1. Torre, L. A. et al. Global cancer statistics, 2012. CA: a cancer journal for clinicians 65, 87, doi: 10.3322/caac.21262 (2015).
2. Prados, J. et al. Colon cancer therapy: recent developments in nanomedicine to improve the efficacy of conventional chemotherapeutic drugs. Anticancer Agents Med Chem 13, 1204 (2013).
3. Carvalho, C. et al. Doxorubicin: the good, the bad and the ugly effect. Curr Med Chem 16, 3267 (2009).
4. Sartiano, G. P., Lynch, W. E. & Bullington, W. D. Mechanism of action of the anthracycline anti-tumor antibiotics, doxorubicin, daunomycin and rubidazone: preferential inhibition of DNA polymerase alpha. The Journal of antibiotics 32, 1038 (1979).
5. Effenberger-Neidnicht, K. & Schobert, R. Combinatorial effects of thymoquinone on the anti-cancer activity of doxorubicin. Cancer Chemother Pharmacol 67, 867, doi: 10.1007/s00280-010-1386-x (2011).
6. Sun, H. et al. Reversal of P-glycoprotein-mediated multidrug resistance by the novel tetrandrine derivative W6. J Asian Nat Prod Res 17, 638, doi: 10.1080/10286020.2015.1047772 (2015).
7. Abdallah, H. M., Al-Abd, A. M., El-Dine, R. S. & El-Halawany, A. M. P-glycoprotein inhibitors of natural origin as potential tumor chemo-sensitizers: A review. J Adv Res 6, 45, doi: 10.1016/j.jare.2014.11.008 (2015).
8. Lai, G. M., Chen, Y. N., Mickley, L. A., Fojo, A. T. & Bates, S. E. P-glycoprotein expression and schedule dependence of adriamycin cytotoxicity in human colon carcinoma cell lines. International journal of cancer 49, 696 (1991)
9. Soliman, F. M. et al. Cytotoxic activity of acyl phloroglucinols isolated from the leaves of Eucalyptus cinerea F. Muell. ex Benth. cultivated in Egypt. Scientific reports 4, 5410, doi: 10.1038/srep05410 (2014).
10. Tolba, M. F. et al. Caffeic acid phenethyl ester synergistically enhances docetaxel and paclitaxel cytotoxicity in prostate cancer cells. IUBMB life 65, 716, doi: 10.1002/iub.1188 (2013).
11. Nawwar, M. A. et al. Cytotoxic isoferulic acidamide from Myricaria germanica (Tamaricaceae). Plant Signal Behav 8, e22642, doi: 10.4161/psb.22642 (2013).
12. Alarif, W. M. et al. Selective cytotoxic effects on human breast carcinoma of new methoxylated flavonoids from Euryops arabicus grown in Saudi Arabia. European journal of medicinal chemistry, 201, 66, doi: 10.1016/j.ejmech.2013.05.025 (2013).
13. Nawwar, M. A. et al. Cytotoxic ellagitannins from Reaumuria vermiculata. Fitoterapia 83, 1256, doi: 10.1016/j.fitote.2012.06.007 (2012).
14. Mahmoud, A. M., Al-Abd, A. M., Lightfoot, D. A. & El-Shemy, H. A. Anti-cancer characteristics of mevinolin against three different solid tumor cell lines was not solely p53-dependent. J Enzyme Inhib Med Chem 27, 673, doi: 10.3109/14756366.2011.607446 (2012).
15. Aboul-Enein, A. M. et al. Eichhornia crassipes (Mart) solms: from water parasite to potential medicinal remedy. Plant Signal Behav 6, 834 (2011).
16. Guerrero, R. F., Garcia-Parrilla, M. C., Puertas, B. & Cantos-Villar, E. Wine, resveratrol and health: a review. Natural product communications 4, 658 (2009).
17. Chan, M. M. Antimicrobial effect of resveratrol on dermatophytes and bacterial pathogens of the skin. Biochemical pharmacology 63, 99 (2002).
18. Brisdelli, F., D'Andrea, G. & Bozzi, A. Resveratrol: a natural polyphenol with multiple chemopreventive properties. Current drug metabolism 10, 530 (2009).
19. Dobrzynska, M. M. Resveratrol as promising natural radioprotector. A review. Rocz Panstw Zakl Hig 64, 255 (2013).
20. Tresguerres, I. F. et al. Resveratrol as anti-aging therapy for age-related bone loss. Rejuvenation research 17, 439, doi: 10.1089/rej.2014.1551 (2014).
21. Wu, M. et al. Resveratrol delays polycystic kidney disease progression through attenuation of nuclear factor kappaB-induced inflammation. Nephrology, dialysis, transplantation (In press), doi: 10.1093/ndt/gfw058 (2016).
22. Chang, G. R., Chen, P. L., Hou, P. H. & Mao, F. C. Resveratrol protects against diet-induced atherosclerosis by reducing low-density lipoprotein cholesterol and inhibiting inflammation in apolipoprotein E-deficient mice. Iranian journal of basic medical sciences 18, 1063 (2015).
23. Abdel-Wahab, B. A. & Abdel-Wahab, M. M. Protective effect of resveratrol against chronic intermittent hypoxia-induced spatial memory deficits, hippocampal oxidative DNA damage and increased p47Phox NADPH oxidase expression in young rats. Behavioural brain research 305, 65, doi: 10.1016/j.bbr.2016.02.030 (2016).
24. Gomez, L. S. et al. Resveratrol decreases breast cancer cell viability and glucose metabolism by inhibiting 6-phosphofructo-1-kinase. Biochimie 95, 1336, doi: 10.1016/j.biochi.2013.02.013 (2013).
25. Hao, Y. Q. et al. Study of apoptosis related factors regulatory mechanism of resveratrol to human skin squamous cell carcinoma A431 xenograft in nude mice. Zhonghua yi xue za zhi 93, 464 (2013).
26. Kaminski, B. M., Steinhilber, D., Stein, J. M. & Ulrich, S. Phytochemicals resveratrol and sulforaphane as potential agents for enhancing the anti-tumor activities of conventional cancer therapies. Curr Pharm Biotechnol 13, 137 (2012).
27. Liu, P. et al. Resveratrol induces apoptosis of pancreatic cancers cells by inhibiting miR-21 regulation of BCL-2 expression. Clinical & translational oncology: official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 15, 741, doi: 10.1007/s12094-012-0999-4 (2013).
28. Al-Abd, A. M. et al. Resveratrol enhances the cytotoxic profile of docetaxel and doxorubicin in solid tumour cell lines in vitro. Cell Prolif 44, 591, doi: 10.1111/j.1365-2184.2011.00783.x (2011).
29. Szekeres, T., Saiko, P., Fritzer-Szekeres, M., Djavan, B. & Jager, W. Chemopreventive effects of resveratrol and resveratrol derivatives. Ann N Y Acad Sci 1215, 89, doi: 10.1111/j.1749-6632.2010.05864.x (2011).
30. Elford, H. L., Wampler, G. L. & van't Riet, B. New ribonucleotide reductase inhibitors with antineoplastic activity. Cancer Res 39, 844 (1979).
31. Fritzer-Szekeres, M. et al. Iron binding capacity of didox (3,4-dihydroxybenzohydroxamic acid) and amidox (3,4-dihydroxybenzamidoxime) new inhibitors of the enzyme ribonucleotide reductase. Life sciences 61, 2231 (1997).
32. Inayat, M. S. et al. Didox (a novel ribonucleotide reductase inhibitor) overcomes Bcl-2 mediated radiation resistance in prostate cancer cell line PC-3. Cancer Biol Ther 1, 539 (2002).
33. Raje, N. et al. Didox, a ribonucleotide reductase inhibitor, induces apoptosis and inhibits DNA repair in multiple myeloma cells. Br J Haematol 135, 52, doi: 10.1111/j.1365-2141.2006.06261.x (2006).
34. Wakisaka, N., Yoshizaki, T., Raab-Traub, N. & Pagano, J. S. Ribonucleotide reductase inhibitors enhance cidofovir-induced apoptosis in EBV-positive nasopharyngeal carcinoma xenografts. Int J Cancer 116, 640, doi: 10.1002/ijc.21096 (2005).
35. Grusch, M. et al. Activation of caspases and induction of apoptosis by novel ribonucleotide reductase inhibitors amidox and didox. Exp Hematol 29, 623 (2001).
36. Abdel-Latif, G. A. et al. The chemomodulatory effects of resveratrol and didox on herceptin cytotoxicity in breast cancer cell lines. Scientific reports 5, 12054, doi: 10.1038/srep12054 (2015).
37. Turchan, J. et al. Oxidative stress in HIV demented patients and protection ex vivo with novel antioxidants. Neurology 60, 307 (2003).
38. Matsebatlela, T. M., Anderson, A. L., Gallicchio, V. S., Elford, H. & Rice, C. D. 3,4-Dihydroxy-benzohydroxamic acid (Didox) suppresses pro-inflammatory profiles and oxidative stress in TLR4-activated RAW264.7 murine macrophages. Chemico-biological interactions 233, 95, doi: 10.1016/j.cbi.2015.03.027 (2015).
39. Al-Abd, A. M., Al-Abbasi, F. A., Asaad, G. F. & Abdel-Naim, A. B. Didox potentiates the cytotoxic profile of doxorubicin and protects from its cardiotoxicity. Eur J Pharmacol 718, 361, doi: 10.1016/j.ejphar.2013.08.009 (2013).
40. Horvath, Z. et al. Combination chemotherapy of BCNU and Didox acts synergystically in 9L glioma cells. Nucleosides, nucleotides & nucleic acids 23, 1531, doi: 10.1081/NCN-200027746 (2004).
41. Lee, T. B., Park, J. H., Min, Y. D., Kim, K. J. & Choi, C. H. Epigenetic mechanisms involved in differential MDR1 mRNA expression between gastric and colon cancer cell lines and rationales for clinical chemotherapy. BMC gastroenterology 8, 33, doi: 10.1186/1471-230X-8-33 (2008).
42. Leonard, G. D., Fojo, T. & Bates, S. E. The role of ABC transporters in clinical practice. The oncologist 8, 411 (2003).
43. Liu, Z. et al. Sinomenine sensitizes multidrug-resistant colon cancer cells (Caco-2) to doxorubicin by downregulation of MDR-1 expression. PLoS One 9, e98560, doi: 10.1371/journal.pone.0098560 (2014).
44. Nielsen, D., Maare, C. & Skovsgaard, T. Cellular resistance to anthracyclines. Gen Pharmacol 27, 251 (1996).
45. Chen, C., Jiang, X., Zhao, W. & Zhang, Z. Dual role of resveratrol in modulation of genotoxicity induced by sodium arsenite via oxidative stress and apoptosis. Food Chem Toxicol 59, 8, doi: 10.1016/j.fct.2013.05.030 (2013).
46. Finucane, D. M., Bossy-Wetzel, E., Waterhouse, N. J., Cotter, T. G. & Green, D. R. Bax-induced caspase activation and apoptosis via cytochrome c release from mitochondria is inhibitable by Bcl-xL. The Journal of biological chemistry 274, 2225 (1999).
47. Miyashita, T. et al. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene 9, 1799 (1994).
48. Pucci, B., Kasten, M. & Giordano, A. Cell cycle and apoptosis. Neoplasia (New York, NY) 2, 291 (2000).
49. Zhang, Z. et al. Genistein induces G2/M cell cycle arrest and apoptosis via ATM/p53-dependent pathway in human colon cancer cells. Int J Oncol 43, 289, doi: 10.3892/ijo.2013.1946 (2013).
50. Moll, U. M., Marchenko, N. & Zhang, X. K. p53 and Nur77/TR3 - transcription factors that directly target mitochondria for cell death induction. Oncogene 25, 4725, doi: 10.1038/sj.onc.1209601 (2006).
51. Cook, G. J., Caudell, D. L., Elford, H. L. & Pardee, T. S. The efficacy of the ribonucleotide reductase inhibitor Didox in preclinical models of AML. PLoS One 9, e112619, doi: 10.1371/journal.pone.0112619 (2014).
52. Schuler, M., Bossy-Wetzel, E., Goldstein, J. C., Fitzgerald, P. & Green, D. R. p53 induces apoptosis by caspase activation through mitochondrial cytochrome c release. The Journal of biological chemistry 275, 7337 (2000).
53. Hinz, S. et al. Bcl-XL protects pancreatic adenocarcinoma cells against CD95- and TRAIL-receptor-mediated apoptosis. Oncogene 19, 5486, doi: 10.1038/sj.onc.1203936 (2000).
54. Figul, M., Soling, A., Dong, H. J., Chou, T. C. & Rainov, N. G. Combined effects of temozolomide and the ribonucleotide reductase inhibitors didox and trimidox in malignant brain tumor cells. Cancer Chemother Pharmacol 52, 41, doi: 10.1007/s00280-003-0611-2 (2003).
55. Cervantes, A., Pinedo, H. M., Lankelma, J. & Schuurhuis, G. J. The role of oxygen-derived free radicals in the cytotoxicity of doxorubicin in multidrug resistant and sensitive human ovarian cancer cells. Cancer Lett 41, 169 (1988).
56. Mayhew, C. N. et al. In vivo and in vitro comparison of the short-term hematopoietic toxicity between hydroxyurea and trimidox or didox, novel ribonucleotide reductase inhibitors with potential anti-HIV-1 activity. Stem Cells 17, 345, doi: 10.1002/stem.170345 (1999).
57. Kanno, S. et al. Preventive effect of trimidox on oxidative stress in U937 cell line. Biol Pharm Bull 30, 994 (2007).
58. Zhang, M., Zhou, X. & Zhou, K. Resveratrol inhibits human nasopharyngeal carcinoma cell growth via blocking pAkt/p70S6K signaling pathways. Int J Mol Med 31, 621, doi: 10.3892/ijmm.2013.1237 (2013).
59. Oi, N. et al. Resveratrol, a red wine polyphenol, suppresses pancreatic cancer by inhibiting leukotriene A(4)hydrolase. Cancer Res 70, 9755, doi: 10.1158/0008-5472.CAN-10-2858 (2010).
60. Ling, Y. H., el-Naggar, A. K., Priebe, W. & Perez-Soler, R. Cell cycle-dependent cytotoxicity, G2/M phase arrest, and disruption of p34cdc2/cyclin B1 activity induced by doxorubicin in synchronized P388 cells. Mol Pharmacol 49, 832 (1996).
61. Zhou, R., Fukui, M., Choi, H. J. & Zhu, B. T. Induction of a reversible, non-cytotoxic S-phase delay by resveratrol: implications for a mechanism of lifespan prolongation and cancer protection. British journal of pharmacology 158, 462, doi: BPH268 [pii]10.1111/j.1476-5381.2009.00268.x (2009).
62. Mittal, A., Tabasum, S. & Singh, R. P. Berberine in combination with doxorubicin suppresses growth of murine melanoma B16F10 cells in culture and xenograft. Phytomedicine 21, 340, doi: 10.1016/j.phymed.2013.09.002 (2014).
63. Songgang, L. et al. Somatostatin enhances the chemosensitivity of GBC-SD cell line to doxorubicin through arresting the cell cycle to S phase rather than through the P53/Bax-depended apoptosis way in vitro. Hepato-gastroenterology 56, 1253 (2009).
64. Tyagi, A. K., Singh, R. P., Agarwal, C., Chan, D. C. & Agarwal, R. Silibinin strongly synergizes human prostate carcinoma DU145 cells to doxorubicin-induced growth Inhibition, G2-M arrest, and apoptosis. Clin Cancer Res 8, 3512 (2002).
65. Skehan, P. et al. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 82, 1107 (1990).
66. Chou, T. C. & Talalay, P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Advances in enzyme regulation 22, 27 (1984).
67. Longo, M. C., Berninger, M. S. & Hartley, J. L. Use of uracil DNA glycosylase to control carry-over contamination in polymerase chain reactions. Gene 93, 125 (1990).
68. Neyfakh, A. A. Use of fluorescent dyes as molecular probes for the study of multidrug resistance. Experimental cell research 174, 168, doi: 0014-4827(88)90152-8 [pii] (1988).